Geron (GERN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
The annual meeting will be held virtually on May 20, 2026, with shareholders able to vote and submit questions online.
Four main proposals are up for vote: election of three directors, amendment of the 2018 Equity Incentive Plan, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditor.
The board recommends voting in favor of all proposals.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect three Class III directors for terms expiring in 2029.
Proposal 2: Approve amendment to the 2018 Equity Incentive Plan, increasing shares available by 4,500,000 and incentive stock option limit by 9,000,000.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Ratify Ernst & Young LLP as independent auditor for 2026.
No other shareholder proposals were received for this meeting.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; CEO is the only non-independent director.
Board is classified into three staggered classes; directors serve three-year terms.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Board leadership is separated between Chair and CEO roles.
Board diversity includes four women and five men as of March 2026.
Latest events from Geron
- Imetelstat anchors second-line MDS therapy, with strong growth and pivotal myelofibrosis data ahead.GERN
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Votes include director elections, equity plan changes, executive pay, and auditor ratification.GERN
Proxy filing7 Apr 2026 - RYTELO net revenue hit $184M in 2025, with 2026 guidance set at $220M-$240M and strong demand growth.GERN
Q4 20257 Apr 2026 - RYTELO drives robust growth with global expansion plans and pivotal MF trial data expected in 2026.GERN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - RYTELO targets strong growth in 2025, supported by market trends, ISTs, and global expansion.GERN
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - RYTELO drives revenue growth and clinical leadership in LR-MDS, with expansion into new markets ahead.GERN
Corporate presentation25 Feb 2026 - FDA approval and U.S. launch of RYTELO drive early revenue and strong financial position.GERN
Q2 20242 Feb 2026 - FDA approves first telomerase inhibitor for transfusion-dependent low-risk MDS, enabling broad access.GERN
FDA Announcement1 Feb 2026 - RYTELO's Q3 launch drove $28.2M revenue and $375M in new capital, fueling future growth.GERN
Q3 202416 Jan 2026